Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y Posted byZacks Equity Research February 25, 2022 Leave a comment on Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.